PDCD1 and cancer: Secondly, tocilizumab was used in patients with advanced cancers receiving a systemic anticancer treatment, cytotoxic agents, or PD-1/PD-L1 Abs; when PIS deteriorated the clinical condition, a transient administration of tocilizumab enabled to alleviate clinical symptoms in all patients.